The purposes of this study were to determine whether the serum of patients with congestive heart failure (CHF) can induce apoptosis of endothelial cells and to elucidate the underlying mechanisms. Moreover, the effect of the beta-blocker carvedilol was investigated. BACKGROUND Congestive heart failure is associated with impaired endothelial function in the peripheral systemic vasculature and with systemic release of inflammatory cytokines. Pro-inflammatory cytokines have been shown to induce endothelial cell apoptosis in vitro. Therefore, we hypothesized that CHF is associated with enhanced apoptosis of endothelial cells.
Increased peripheral vascular resistance is a hallmark of congestive heart failure (CHF) (1) . The impaired functional capacity of peripheral blood vessels to dilate in response to increased flow is a major determinant of the degree of exercise intolerance, one of the most important clinical features of patients with heart failure (2, 3) . The deficit in peripheral vasodilator capacity results from attenuated vascular endothelial function (4) and has been attributed to a loss of the ability of the endothelium to release nitric oxide in response to physiologic stimuli (5, 6) . Immunologic and inflammatory responses may play a pathogenetic role in the development of CHF (7) . Congestive heart failure is associated with elevated circulatory levels of pro-inflammatory cytokines, such as interleukin-1, interleukin-6 and tumor necrosis factor-alpha (TNF-alpha) (8 -10) , as well as C-C chemokines (11) . All these cytokines cause endothelial cell dysfunction either directly or through the generation of reactive oxygen species (12, 13) , providing a potential pathophysiologic link between the loss of normal endothelial function and CHF.
Apoptosis or programmed cell death is a characteristic feature of endothelial cell activation after stimulation of systemic inflammatory responses in vivo (14) . In addition, incubation with pro-inflammatory cytokines and reactive oxygen species induces endothelial cell apoptosis in vitro (12, 13, 15) . Apoptosis is morphologically characterized by cell shrinkage, membrane blebbing, chromatin condensation and deoxyribonucleic acid (DNA) fragmentation (16) . These stereotypical changes are accomplished by complex biochemical events involving the activation of cysteine proteases called "caspases" (17) . The activation of initiator caspases by various stimuli triggers the release of mitochondrial cytochrome c, which in turn activates the multiprotein "poptosome" ensemble, composed of Apaf-1, cytochrome c and pro-caspase-9 (18, 19) . Activation of pro-caspase-9 then processes and activates other caspases to orchestrate the biochemical execution of cell death (20) .
A very recent study suggested that the serum of patients with CHF induces endothelial cell apoptosis in vitro (21) . Therefore, we investigated the signaling cascade involved in heart failure serum-induced apoptosis of endothelial cells.
In addition, we examined whether apoptosis also occurs in vivo, thus providing a potential mechanistic link for the impaired endothelial function in patients with CHF. Moreover, we examined the effects of the neurohormonal antagonist carvedilol, which has been shown to exert beneficial effects in patients with CHF (22) . The results of our studies demonstrate that the serum of patients with CHF induces apoptosis of endothelial cells through activation of the caspase cascade. Carvedilol suppresses activation of the caspase cascade by inhibiting mitochondrial cytochrome c release and significantly reduces endothelial cell apoptosis induced by the serum of patients with CHF.
METHODS
Patients and control subjects. Fifteen patients with CHF were studied (Table 1) . Patients received standard treatment for heart failure, consisting of angiotensin-converting enzyme inhibitors, diuretics and digitalis. Patients with elevated serum creatinine levels (Ͼ1.4 mg/dl), infectious or pulmonary disease or myocardial infarction within the last three months were not included. In addition, six patients receiving carvedilol treatment (6.25 to 50 mg/day; plasma levels 14.99 Ϯ 7.4 g/liter) were studied. Eleven healthy age-matched volunteers (six men and five women; mean age 50 Ϯ 11.6 years) with no history of cardiac disease served as the control group. Venous blood was drawn into 10-ml serum tubes without additives. After centrifugation, serum aliquots were frozen at Ϫ80°C. The Ethics Committee of the University of Frankfurt approved the study protocols, and written, informed consent was obtained from all study participants. Germany) ; Z-Val-Ala-DL-Asp-fluoromethylketone (ZVADA-fmk) was from Bachem (Heidelberg, Germany); and human recombinant TNF-alpha and anisomycin were from Sigma (Munich, Germany). Cell culture. The human umbilical vein endothelial cells (HUVECs) (Cell Systems/Clonetics, Solingen, Germany) were cultured in endothelial basal medium supplemented with hydrocortisone, bovine brain extract, gentamicin, amphotericin B, epidermal growth factor and 10% fetal calf serum until the third passage before experiments were performed. Detection of apoptosis. Assessment of apoptotic nuclei and internucleosomal DNA laddering were performed as described previously (12, 23) . The amount of apoptotic particles in human plasma samples was measured according to Aupeix et al. (24) . Results were expressed as nanomolar phosphatidylserine normalized by a standard curve using liposomes of a defined composition. In addition to apoptosis assessment, cell viability was determined with the 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay, as previously published (12) . Cytokine measurements. Tumor necrosis factor-alpha and soluble TNF-receptor 1 (sTNF-R1) serum levels were measured by commercially available enzyme-linked immunosorbent assay kits (R & D Systems, Wiesbaden, Germany). Mitogen-activated protein kinase (MAPK) assays. The activity of c-JUN NH 2 -terminal kinase (JNK) was detected by using a nonradioactive assay (New England BioLabs, Frankfurt am Main, Germany). Phosphorylation of p38 was assayed by Western blotting using a phospho-specific antibody against phosphorylated Thr-180 and Tyr-182 of p38 MAPK (New England Biolabs). Plasmids and transfection. Caspase-8 was cloned into the pcDNA3.1 vector, as previously described (25) . The HUVECs were transiently co-transfected with 3-g plasmids using Superfect (Qiagen, Hilden, Germany) (23) . Transfected cells were identified by beta-galactosidase staining. Stained cells were analyzed by two investigators in blinded manner, and the results were expressed as dead/ viable cells ϫ 100. Caspase-3-like enzyme activity. Caspase-3-like activity was detected by measuring cleavage of the fluorogenic substrate 7-amino-4-coumarin-Asp-Glu-Val-Asp, as previously published (12) . Cytochrome c release. The mitochondrial versus cytosolic fractions were separated, Western blotted and probed with anti-cytochrome c antibody (PharMingen, San Diego, California), as described (26).
Reagents
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RESULTS
Serum of patients with heart failure induces endothelial cell apoptosis. Exposure of HUVECs to the serum of patients with CHF led to a significant increase in apoptosis compared with the serum of healthy volunteers (4.3 Ϯ 0.7% 
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Endothelial Cell Apoptosis in Heart Failure vs. 2.9 Ϯ 0.9%), as demonstrated by morphological analysis of cell nuclei (Fig. 1A) , as well as by DNA laddering (Fig.  1B) . Moreover, CHF serum significantly reduced cell viability (Fig. 1C) . The extent of serum-induced endothelial cell apoptosis correlated with the functional status of the patients (Fig. 1D) . The serum of patients with severe CHF (NYHA class III and IV) revealed a significantly enhanced pro-apoptotic activity compared with the serum of patients in class II (p Ͻ 0.05). To test the in vivo relevance of these in vitro findings, apoptotic particles were measured in human plasma. As shown in Figure 1E , plasma levels of apoptotic particles were significantly increased in patients with CHF compared with healthy control subjects. The pro-apoptotic cytokine TNF-alpha has been shown to be elevated in CHF (10) . Indeed, serum levels of TNF-alpha and sTNF-R1 were significantly increased in patients with CHF compared with healthy volunteers (Fig.  2A) . Apoptosis induction in vitro correlated with TNFalpha serum levels (Fig. 2B) . A similar correlation was observed between apoptosis rates and sTNF-R1 serum levels (r ϭ 0.517, p ϭ 0.007), suggesting a link between pro-inflammatory cytokine levels and endothelial cell apoptosis in CHF.
Because activation of the caspase cascade is central to apoptosis signaling, we investigated whether serum-induced apoptosis of endothelial cells involves caspase activation. Complete inhibition of caspases by ZVAD-fmk abolished serum-induced endothelial cell apoptosis (Fig. 3A) . Thus, apoptosis of endothelial cells induced by the serum of patients with CHF depends on activation of the caspase cascade. Carvedilol suppresses endothelial cell apoptosis induced by serum of patients with CHF. Carvedilol has been shown to be effective in the management of CHF (22) . Therefore, we tested the effect of carvedilol on endothelial cell apoptosis. The addition of carvedilol suppressed the Figure 2 . Serum levels of TNF-alpha and sTNF-R1. A, Serum levels of TNF-alpha and sTNF-R1 in patients with CHF (n ϭ 15) and in control subjects (n ϭ 11). *p Ͻ 0.01 vs. control group. **p Ͻ 0.005 vs. control group. B, Correlation of TNF-alpha serum levels with apoptosis rates in HUVECs after exposure to serum for 18 h (n ϭ 26).
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induction of apoptosis by the serum of patients with CHF to control levels (Fig. 3, A and B) . Moreover, carvedilol slightly but not significantly decreased apoptosis of HUVECs in the presence of control serum (20.6 Ϯ 15.2% inhibition). Next, we tested the in vivo relevance of the apoptosis-suppressive effect of carvedilol. Apoptosis induction by the serum of patients with CHF receiving carvedilol treatment (n ϭ 6) was significantly lower compared with the serum of patients without treatment (3.5 Ϯ 0.8 vs. 4.5 Ϯ 0.7%, p Ͻ 0.05). Carvedilol inhibits apoptosis by means of its antioxidative properties. To characterize the mechanisms by which carvedilol prevents apoptosis, the effects of carvedilol on stimulus-induced apoptosis were determined in vitro. Coincubation with carvedilol dose-dependently reduced TNFalpha-induced apoptosis in endothelial cells (Fig. 3, C and  D ). Therefore, we tested whether the beta-adrenoreceptor antagonistic or the antioxidative effect accounts for the antiapoptotic action of carvedilol. The hydroxylated analogue BM91.0228, which is a potent antioxidant but lacks beta-blocking activity, led to a similar suppression of apoptosis, whereas both propranolol, a beta-blocker without antioxidative properties, and the alpha-blocker prazosin had no significant effect on TNF-alpha-induced apoptosis ( Fig.  3D ; data not shown). Thus, inhibition of endothelial cell apoptosis by carvedilol appears to be due to its antioxidative properties. Carvedilol inhibits apoptosis signaling by suppressing cytochrome c release. Previous studies using cardiac myocytes have suggested that the antiapoptotic effect of carve- Endothelial Cell Apoptosis in Heart Failure dilol is mediated through inhibition of the stress-activated JNK pathway (27) . In endothelial cells, TNF-alphainduced activation of JNK was not prevented by coincubation with carvedilol (Fig. 4A) . Carvedilol also had no effect on TNF-alpha-induced activation of p38 MAPK (Fig. 4B) . Thus, the antiapoptotic effect of carvedilol on endothelial cells appears to be mediated by other mechanisms. Therefore, we determined the effect of carvedilol on the distal pro-apoptotic cysteine protease caspase-3 (28) . Both carvedilol and its antioxidative analogue BM91.0228, but not propranolol, significantly inhibited TNF-alphainduced caspase-3 activation (Fig. 5A) . Moreover, carvedilol and BM91.0228 significantly suppressed apoptosis induction by overexpression of caspase-8, which links cytokine receptor stimulation to the caspase cascade. (Fig. 5B ). Next, we tested whether interference with the mitochondrial cytochrome c release may account for the antiapoptotic effect of carvedilol. Co-incubation with carvedilol significantly reduced the TNF-alpha-triggered release of cytochrome c into the cytosol (Fig. 5C ). These results suggest that carvedilol stabilizes the mitochondrial membrane in endothelial cells and thus prevents TNF-alpha-mediated caspase-3 activation.
DISCUSSION
The activation of endothelial cells, which results in impaired peripheral vasoactivity, may play an important role in the pathophysiology of CHF. The results of the present study confirm recently published data (21) showing that the serum of patients with CHF induces endothelial cell apoptosis in vitro. More importantly, the increase of plasma-shed membrane particles in patients with CHF indicates that apoptotic cell death also occurs in vivo. The pro-apoptotic serum effects correlate with the systemic inflammation indicated by increased levels of TNF-alpha and sTNF-R1 and suggest that circulating factors may directly damage endothelial cells in CHF. Mechanistically, our data demonstrate that the injury to endothelial cells is mediated by activation of the caspase cascade. Carvedilol, which has been shown to have 
beneficial effects in patients with CHF, inhibits activation of the caspase cascade by blocking mitochondrial cytochrome c release and completely suppresses apoptosis induction in endothelial cells by the serum of patients with CHF. These findings may provide novel and important insights into the potential mechanisms underlying the beneficial effects of carvedilol.
Involvement of apoptosis in cytokine-mediated endothelial injury in CHF.
Congestive heart failure is associated with increased circulating levels of pro-inflammatory cytokines (7-9). The inflammatory response correlates with the severity of CHF symptoms (10, 11) and has been suggested to play a pathogenetic role in the development of CHF (29) .
The results of the present study considerably extend these findings by demonstrating that increased circulating levels of TNF-alpha and sTNF-R1 in patients with CHF are associated with the induction of endothelial cell apoptosis in vitro. This could provide a mechanistic link between CHF and endothelial dysfunction. Mechanisms of endothelial cell apoptosis induction in CHF. The precise serum factor(s) responsible for activation of the caspase cascade in endothelial cells remain to be determined. We have previously shown that TNF-alpha (12) , reactive oxygen species (13, 30) and angiotensin II (31) all represent potent activators of the caspase cascade, leading to endothelial cell apoptosis. All these factors are elevated in serum of patients with CHF (10, 32, 33) . Serum activation of endothelial cells was followed by apoptosis induction, even in the presence of neutralizing antibodies against TNFalpha (data not shown) (21) . Thus, mediators other than TNF-alpha contribute to the activation of caspases in endothelial cells. However, regardless of the identity of the caspase activator(s), apoptosis induction was directly related to the severity of symptoms in patients with CHF, reflecting the relevance of endothelial cell apoptosis as a pathogenetic mechanism in this disease.
Effect of carvedilol on endothelial cell apoptosis in CHF.
Carvedilol, which reduces mortality and worsening of symptoms in patients with CHF (22, 34) , leads to peripheral vasodilation through blockade of alpha 1 receptors and acts as an antioxidant, in addition to its nonselective betablocking activity (35) . Recently, some of the beneficial effects of carvedilol have been suggested to rely on the inhibition of cardiac myocyte apoptosis (27) , which may contribute to the progression of heart failure (36) . The present study now provides evidence for an additional vasculoprotective effect of carvedilol-namely, the suppression of increased endothelial cell apoptosis induced by the serum of patients with CHF. In contrast with cardiac myocytes, the antiapoptotic effect of carvedilol in endothelial cells was not related to JNK or p38 inhibition, but involved the reduction of mitochondrial cytochrome c release. The mitochondrial membrane "stabilizing" effect of carvedilol is mediated through its antioxidative action, because the analogue BM91.0228, which has no betablocking activity, was equipotent to carvedilol in apoptosis inhibition. The antioxidative capacity of carvedilol in vivo has recently been documented by a reduction in the oxidative modification of lipid products in volunteers during a seven-day treatment period with carvedilol (37) . However, the results of the present study do not discard the possibility that beta-blockers, with no direct in vitro antioxidant properties, might likewise reduce the incidence of endothelial cell apoptosis in vivo in patients with CHF. Indeed, it has recently been demonstrated that carvedilol and metoprolol treatment is associated with equipotent reductions in systemic oxidative stress, as measured by thiobarbituric acid Endothelial Cell Apoptosis in Heart Failure reactive substances (TBARS) in patients with CHF (38) . Importantly, TBARS formation directly correlates with the functional severity of CHF as assessed by the NYHA classification (32) . Therefore, the functional improvement of patients with CHF receiving beta-blocker therapy might be associated with reduced oxidative stress, which will translate into a beneficial effect upstream of caspase activation and cytochrome c release, irrespective of the direct antioxidant properties of the beta-blocking agent.
Conclusions.
The results of the present study demonstrate that the serum of patients with CHF potently induces apoptosis of endothelial cells, providing another possible mechanistic clue in the pathogenesis of endothelial dysfunction in patients with CHF. The inhibition of endothelial cell apoptosis by carvedilol through prevention of mitochondrial cytochrome c release discloses a novel mechanism, which might contribute to its beneficial effects in the management of patients with CHF. In general, interventions that interfere with the induction of apoptosis of endothelial cells may provide a novel therapeutic target in patients with CHF.
